Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis
2019
Introduction: Levels of the inflammatory cytokine IL-6 and its associated biomarker CRP, the production of which is predominantly stimulated by IL-6, are strongly correlated with CV outcomes in CKD...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
3
Citations
NaN
KQI